Baxter International Inc. (BAX)
BAX Price and Sentiment
BAX Latest news
Baxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility2021-11-11 09:00
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter announced a $100M investment in its manufacturing facility in Halle/Westfalen, Germany that will add new capacity and capabilities.
Baxter Highlights New Data Indicating Sharesource Digital Health Platform for Home Dialysis May Improve Survival and Reduce Hospitalizations2021-11-08 08:30
DEERFIELD, Ill.--(BUSINESS WIRE)-- #digitalhealth--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing kidney patients may experience a survival rate nearly two-times higher and a prolonged time to an adverse event (AE) and hospitalization when the Sharesource remote patient management digital health platform is used to help manage home automated peritoneal dialysis (APD).1 The new data was presented during the American Society of Nephrology's annual Kidney W
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 9:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through May 21, 2022. About Baxter Every day, millions of patients and caregiver
Baxter International Inc (NYSE: BAX) posted Q3 revenue of $3.23 billion, in line with the consensus, up 9% on a reported basis, 7% on a constant currency basis, and 6% on an operational basis. Adjusted EPS of $1.02 increased 23% and surpassed the estimate of $0.94.
Baxter International Inc. (BAX) CEO Joe Almeida on Q3 2021 Results - Earnings Call Transcript
Baxter's (BAX) third-quarter results reflect robust performance across all its business units.
Baxter (BAX) delivered earnings and revenue surprises of 8.51% and 0.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021. “Baxter's essential products, diverse portfolio and global scale continue to fuel our operations in 2021,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “This month marks Baxter's 90th anniversary. Our employees have been at the heart of our success for nine decades and remain as determined as ever
Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.